CUE
Income statement / Annual
Last year (2023), Cue Biopharma, Inc.'s total revenue was $5.49 M,
an increase of 340.88% from the previous year.
In 2023, Cue Biopharma, Inc.'s net income was -$50.73 M.
See Cue Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$5.49 M |
$1.25 M |
$14.94 M |
$3.15 M |
$3.46 M |
$1.14 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$38.10 M
|
$1.81 M
|
-$1.78 M
|
$33.55 M
|
$27.49 M
|
$28.54 M
|
$419,568.00
|
$202,085.00
|
$44,815.00
|
| Gross Profit |
-$32.61 M
|
-$560,828.00
|
$16.72 M
|
-$30.39 M
|
-$24.03 M
|
-$27.40 M
|
-$419,568.00
|
-$202,085.00
|
-$44,815.00
|
| Gross Profit Ratio |
-5.94
|
-0.45
|
1.12
|
-9.63
|
-6.95
|
-23.98
|
0
|
0
|
0
|
| Research and Development Expenses |
$40.80 M
|
$38.58 M
|
$41.35 M
|
$33.55 M
|
$27.49 M
|
$28.54 M
|
$18.90 M
|
$5.69 M
|
$1.50 M
|
| General & Administrative Expenses |
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$12.74 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
$425,081.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$12.74 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
$425,081.00
|
| Other Expenses |
-$37.94 M
|
$0.00
|
$0.00
|
$0.00
|
$64,000.00
|
$165,337.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$19.54 M
|
$54.75 M
|
$58.65 M
|
$48.20 M
|
$40.23 M
|
$39.84 M
|
$23.23 M
|
$7.66 M
|
$1.93 M
|
| Cost And Expenses |
$57.64 M
|
$54.75 M
|
$58.65 M
|
$48.20 M
|
$40.23 M
|
$39.84 M
|
$23.23 M
|
$7.66 M
|
$1.93 M
|
| Interest Income |
$2.66 M
|
$928,242.00
|
$45,898.00
|
$463,914.00
|
$419,000.00
|
$376,008.00
|
$35.00
|
$52.00
|
$0.00
|
| Interest Expense |
$1.25 M
|
$713,815.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.44 M
|
$1.81 M
|
-$1.78 M
|
$1.06 M
|
$5.35 M
|
$760,011.00
|
$419,568.00
|
$202,085.00
|
$44,815.00
|
| EBITDA |
-$46.05 M |
-$50.49 M |
-$45.44 M |
-$43.99 M |
-$35.96 M |
-$37.94 M |
-$22.81 M |
-$7.46 M |
-$1.88 M |
| EBITDA Ratio |
-8.39
|
-40.77
|
-2.93
|
-13.94
|
-10.63
|
-33.2
|
0
|
0
|
0
|
| Operating Income Ratio |
-9.5
|
-42.74
|
-2.93
|
-14.28
|
-10.63
|
-33.87
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.42 M
|
$215,000.00
|
$45,898.00
|
$463,914.00
|
$482,790.00
|
$541,345.00
|
$35.00
|
$52.00
|
$0.00
|
| Income Before Tax |
-$50.73 M
|
-$53.01 M
|
-$43.67 M
|
-$44.58 M
|
-$36.29 M
|
-$38.16 M
|
-$23.23 M
|
-$7.66 M
|
-$1.93 M
|
| Income Before Tax Ratio |
-9.24
|
-42.57
|
-2.92
|
-14.13
|
-10.49
|
-33.39
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$214,427.00
|
$495,000.00
|
$206,250.00
|
$412,000.00
|
$825,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$50.73 M
|
-$52.80 M
|
-$44.16 M
|
-$44.78 M
|
-$36.70 M
|
-$38.98 M
|
-$23.23 M
|
-$7.66 M
|
-$1.93 M
|
| Net Income Ratio |
-9.24
|
-42.4
|
-2.96
|
-14.2
|
-10.61
|
-34.12
|
0
|
0
|
0
|
| EPS |
-1.11 |
-1.48 |
-1.41 |
-1.56 |
-1.66 |
-1.94 |
-1.13 |
-0.37 |
-0.0934 |
| EPS Diluted |
-1.11 |
-1.48 |
-1.41 |
-1.56 |
-1.66 |
-1.94 |
-1.13 |
-0.37 |
-0.0934 |
| Weighted Average Shares Out |
$45.75 M
|
$35.65 M
|
$31.29 M
|
$28.69 M
|
$22.04 M
|
$20.13 M
|
$20.64 M
|
$20.64 M
|
$20.64 M
|
| Weighted Average Shares Out Diluted |
$45.75 M
|
$35.65 M
|
$31.29 M
|
$28.69 M
|
$22.04 M
|
$20.13 M
|
$20.64 M
|
$20.64 M
|
$20.64 M
|
| Link |
|
|
|
|
|
|
|
|
|
